Brief: Isofol - Solasia Pharma To Invest SEK 140 Mln In Arfolitixorin Trials In Japan
April 3 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST: SOLASIA PHARMA TO INVEST 140 MSEK IN ARFOLITIXORIN TRIALS IN JAPAN Source text: ID:nMFN15rr51 Further company coverage: ISOFOL.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical reports no Q2 revenue, net loss widens
Brief: Isofol Medical Q2 Net Income SEK -15.729 Million
Brief: Isofol Medical Adds Clinical Trial Sites To Phase Ib/Ii Arfolitixorin Study In Colorectal Cancer
Sweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million